KaleidoScot The Northern end of the rainbow
Johnson & Johnson and partner GlaxoSmithKline PLC subsidiary ViiV Healthcare, which specialises in anti-retroviral drugs, announced yesterday encouraging initial trial results on a drug that could revolutionise HIV treatment. Glaxo said the results from the study showed the investigational, long-acting, injectable combination of Cabotegravir, ViiV Healthcare’s treatment, and Rilpivirine, made by Johnson & Johnson’s Janssen unit, were highly effecting in maintaining viral suppression rates. A single ...
Read More »New injectable drug could keep HIV at bay indefinitely
